<DOC>
	<DOCNO>NCT00001990</DOCNO>
	<brief_summary>To facilitate provision atovaquone ( 566C80 ) patient severe Pneumocystis carinii pneumonia ( PCP ) intolerant and/or unresponsive trimethoprim / sulfamethoxazole ( TMX / SMX ) ; monitor serious adverse event attributable 566C80 .</brief_summary>
	<brief_title>An Open-Label , Uncontrolled Clinical Trial Oral 566C80 Treatment Patients With Severe PCP Who Are Intolerant and/or Unresponsive Therapy With Trimethoprim/Sulfamethoxazole Parenteral Pentamidine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Clinical diagnosis acute severe Pneumocystis carinii pneumonia ( PCP ) . Doselimiting intolerance TMP / SMX parenteral pentamidine . Willingness ability give inform consent . Exclusion Criteria Coexisting Condition : Excluded : Patients history intolerance 566C80 . Patients follow prior condition exclude : History serious doselimiting adverse experience previous 566C80 therapy , think attributable drug . Required : Trimethoprim / sulfamethoxazole ( TMP/SMX ) ; pentamidine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1993</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>atovaquone</keyword>
</DOC>